The European Commission’s Pharmaceutical Sector Inquiry raised significant concerns regarding so-called “reverse payment” patent settlement agreements. In this article, CRA describes the types of information or economic evidence that might facilitate evaluation of the competitive aspects of these settlements. To read the article, click here:
Lexology Index recognizes 44 CRA competition experts globally
This year, 44 CRA experts were named among the leading Competition Economists, with four recognized as Competition Future Leaders – Economists. This...